title: Treatment of hypereosinophilic syndromes--the first 100 years.
abstract: Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timely diagnosis. Tried and true medications such as prednisone, hydroxyurea, and interferon-alpha (IFN-aα) continue to play a valuable role in treating HES and their cost is modest. Newer medications included pegylated forms of IFN-aα and IFN-α2b, first- and second-generation tyrosine kinase inhibitors (imatinib mesylate, nilotinib), and monoclonal antibodies to interleukin (IL)-5 and CD52. The combination of better understanding of HES and better medications now provide the clinician with an improved ability to control unregulated proliferation of eosinophils.
authors.affiliation: Division of Allergic Diseases, Mayo Clinic, Rochester, MN 55905, USA. butterfield.joseph@mayo.edu
authors.forename: J H
authors.initials: JH
authors.lastname: Butterfield
authors.forename: C R
authors.initials: CR
authors.lastname: Weiler
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000998:Antiviral Agents / Q000627:therapeutic use; D001549:Benzamides; D000074301:CD52 Antigen; D006023:Glycoproteins / Q000276:immunology; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000266:history / Q000276:immunology; D000068877:Imatinib Mesylate; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D015848:Interleukin-5 / Q000276:immunology; D010879:Piperazines / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000998:Antiviral Agents; D001549:Benzamides; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; C508599:IL5 protein, human; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015848:Interleukin-5; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000068877:Imatinib Mesylate; D011239:Prednisolone; C498826:nilotinib; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a; D006918:Hydroxyurea